Beneficial effects of oral tilactase on patients with hypolactasia

P. Portincasa, A. Di Ciaula, M. Vacca, R. Montelli, D. Q.H. Wang, G. Palasciano

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: A lactose-free diet is commonly prescribed to subjects with hypolactasia. We tested the effectiveness of a single ingestion of tilactase (a β-d-galactosidase from Aspergillus oryzae) in adults with hypolactasia, previously assessed by lactose H2-breath test. Materials and methods: After measurement of orocecal transit time (OCTT, by lactulose H 2-breath test) and lactose H2-breath testing plus placebo, a total of 134 subjects were positive to hypolactasia and underwent lactose H2-breath testing plus either low (6750 U) or standard (11 250 U) doses of tilactase. The appearance of gastrointestinal symptoms during the tests was monitored. Results: OCTT was longer in malabsorbers (subjects without bloating, abdominal pain and/or diarrhoea, n = 25) than in intolerants (bloating, abdominal pain and/or diarrhoea, n = 109, P < 0.02). Malabsorbers had longer time to H2 peak (P < 0.03), lower H2 peak levels (P < 0.002) and smaller integrated H2 excretion levels (P < 0.005) than intolerants. After tilactase ingestion, integrated H 2 levels were decreased by 75% (low dose) and 87% (standard dose) in malabsorbers, and by 74% (low dose) and 88% (standard dose) in intolerants. In the latter group, total symptom score were decreased by 76% (low dose) and by 88% (standard dose) (P < 0.0001). Conclusion: A single oral administration of tilactase is highly effective in decreasing symptoms and hydrogen excretion of hypolactasia assessed by lactose H2-breath test. If confirmed by long-term observations, ingestion of tilactase might be a better option than exclusion diets in intolerant subjects with hypolactasia.

Original languageEnglish (US)
Pages (from-to)835-844
Number of pages10
JournalEuropean Journal of Clinical Investigation
Volume38
Issue number11
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Lactose Intolerance
Lactose
Breath Tests
Eating
Nutrition
Abdominal Pain
Diarrhea
Galactosidases
Diet
Aspergillus oryzae
Lactulose
Aspergillus
Testing
Oral Administration
Hydrogen
Placebos

Keywords

  • Breath test
  • Lactase
  • Milk

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Beneficial effects of oral tilactase on patients with hypolactasia. / Portincasa, P.; Di Ciaula, A.; Vacca, M.; Montelli, R.; Wang, D. Q.H.; Palasciano, G.

In: European Journal of Clinical Investigation, Vol. 38, No. 11, 01.11.2008, p. 835-844.

Research output: Contribution to journalArticle

Portincasa, P. ; Di Ciaula, A. ; Vacca, M. ; Montelli, R. ; Wang, D. Q.H. ; Palasciano, G. / Beneficial effects of oral tilactase on patients with hypolactasia. In: European Journal of Clinical Investigation. 2008 ; Vol. 38, No. 11. pp. 835-844.
@article{423a94d20b6647ab9a807dc15f080321,
title = "Beneficial effects of oral tilactase on patients with hypolactasia",
abstract = "Background: A lactose-free diet is commonly prescribed to subjects with hypolactasia. We tested the effectiveness of a single ingestion of tilactase (a β-d-galactosidase from Aspergillus oryzae) in adults with hypolactasia, previously assessed by lactose H2-breath test. Materials and methods: After measurement of orocecal transit time (OCTT, by lactulose H 2-breath test) and lactose H2-breath testing plus placebo, a total of 134 subjects were positive to hypolactasia and underwent lactose H2-breath testing plus either low (6750 U) or standard (11 250 U) doses of tilactase. The appearance of gastrointestinal symptoms during the tests was monitored. Results: OCTT was longer in malabsorbers (subjects without bloating, abdominal pain and/or diarrhoea, n = 25) than in intolerants (bloating, abdominal pain and/or diarrhoea, n = 109, P < 0.02). Malabsorbers had longer time to H2 peak (P < 0.03), lower H2 peak levels (P < 0.002) and smaller integrated H2 excretion levels (P < 0.005) than intolerants. After tilactase ingestion, integrated H 2 levels were decreased by 75{\%} (low dose) and 87{\%} (standard dose) in malabsorbers, and by 74{\%} (low dose) and 88{\%} (standard dose) in intolerants. In the latter group, total symptom score were decreased by 76{\%} (low dose) and by 88{\%} (standard dose) (P < 0.0001). Conclusion: A single oral administration of tilactase is highly effective in decreasing symptoms and hydrogen excretion of hypolactasia assessed by lactose H2-breath test. If confirmed by long-term observations, ingestion of tilactase might be a better option than exclusion diets in intolerant subjects with hypolactasia.",
keywords = "Breath test, Lactase, Milk",
author = "P. Portincasa and {Di Ciaula}, A. and M. Vacca and R. Montelli and Wang, {D. Q.H.} and G. Palasciano",
year = "2008",
month = "11",
day = "1",
doi = "10.1111/j.1365-2362.2008.02035.x",
language = "English (US)",
volume = "38",
pages = "835--844",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Beneficial effects of oral tilactase on patients with hypolactasia

AU - Portincasa, P.

AU - Di Ciaula, A.

AU - Vacca, M.

AU - Montelli, R.

AU - Wang, D. Q.H.

AU - Palasciano, G.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: A lactose-free diet is commonly prescribed to subjects with hypolactasia. We tested the effectiveness of a single ingestion of tilactase (a β-d-galactosidase from Aspergillus oryzae) in adults with hypolactasia, previously assessed by lactose H2-breath test. Materials and methods: After measurement of orocecal transit time (OCTT, by lactulose H 2-breath test) and lactose H2-breath testing plus placebo, a total of 134 subjects were positive to hypolactasia and underwent lactose H2-breath testing plus either low (6750 U) or standard (11 250 U) doses of tilactase. The appearance of gastrointestinal symptoms during the tests was monitored. Results: OCTT was longer in malabsorbers (subjects without bloating, abdominal pain and/or diarrhoea, n = 25) than in intolerants (bloating, abdominal pain and/or diarrhoea, n = 109, P < 0.02). Malabsorbers had longer time to H2 peak (P < 0.03), lower H2 peak levels (P < 0.002) and smaller integrated H2 excretion levels (P < 0.005) than intolerants. After tilactase ingestion, integrated H 2 levels were decreased by 75% (low dose) and 87% (standard dose) in malabsorbers, and by 74% (low dose) and 88% (standard dose) in intolerants. In the latter group, total symptom score were decreased by 76% (low dose) and by 88% (standard dose) (P < 0.0001). Conclusion: A single oral administration of tilactase is highly effective in decreasing symptoms and hydrogen excretion of hypolactasia assessed by lactose H2-breath test. If confirmed by long-term observations, ingestion of tilactase might be a better option than exclusion diets in intolerant subjects with hypolactasia.

AB - Background: A lactose-free diet is commonly prescribed to subjects with hypolactasia. We tested the effectiveness of a single ingestion of tilactase (a β-d-galactosidase from Aspergillus oryzae) in adults with hypolactasia, previously assessed by lactose H2-breath test. Materials and methods: After measurement of orocecal transit time (OCTT, by lactulose H 2-breath test) and lactose H2-breath testing plus placebo, a total of 134 subjects were positive to hypolactasia and underwent lactose H2-breath testing plus either low (6750 U) or standard (11 250 U) doses of tilactase. The appearance of gastrointestinal symptoms during the tests was monitored. Results: OCTT was longer in malabsorbers (subjects without bloating, abdominal pain and/or diarrhoea, n = 25) than in intolerants (bloating, abdominal pain and/or diarrhoea, n = 109, P < 0.02). Malabsorbers had longer time to H2 peak (P < 0.03), lower H2 peak levels (P < 0.002) and smaller integrated H2 excretion levels (P < 0.005) than intolerants. After tilactase ingestion, integrated H 2 levels were decreased by 75% (low dose) and 87% (standard dose) in malabsorbers, and by 74% (low dose) and 88% (standard dose) in intolerants. In the latter group, total symptom score were decreased by 76% (low dose) and by 88% (standard dose) (P < 0.0001). Conclusion: A single oral administration of tilactase is highly effective in decreasing symptoms and hydrogen excretion of hypolactasia assessed by lactose H2-breath test. If confirmed by long-term observations, ingestion of tilactase might be a better option than exclusion diets in intolerant subjects with hypolactasia.

KW - Breath test

KW - Lactase

KW - Milk

UR - http://www.scopus.com/inward/record.url?scp=54349083840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349083840&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2008.02035.x

DO - 10.1111/j.1365-2362.2008.02035.x

M3 - Article

VL - 38

SP - 835

EP - 844

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 11

ER -